Series B
$125M
Novo HoldingsJanus Henderson Investors · LeadInvusFranklin TempletonMarshall WaceDeerfield Management4BIO CapitalNorwest Venture PartnersPlatanusMRL Ventures FundAdage Capital Management
Open roles0
Total raised$125M
Team size11-50
Founded · Stage2021 · Series B
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Ray Therapeutics is a Berkeley, California clinical-stage biopharmaceutical company developing optogenetic gene therapies to restore vision in patients with retinal degenerative diseases. Its approach delivers a bioengineered, highly light-sensitive protein to surviving retinal cells via a single intravitreal injection, aiming to restore functional sight regardless of the underlying genetic mutation. Lead candidate RTx-015 is in clinical development for retinitis pigmentosa and holds FDA Regenerative Medicine Advanced Therapy (RMAT) designation, while second program RTx-021 targets macular conditions such as Stargardt disease and geographic atrophy.
Why it matters
Signals from funding, traction, and product direction.
- The Series B was upsized and oversubscribed, signaling strong investor demand ahead of late-stage clinical readouts.
- The round closed weeks after the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to lead candidate RTx-015 for retinitis pigmentosa, unlocking rolling review and potential priority review benefits.
- Lead investor Janus Henderson Investors called RayTx's optogenetic platform a first- and best-in-class technology, joined by new backers Adage Capital, Franklin Templeton, Invus, and Marshall Wace, with follow-on from 4BIO Capital, Deerfield, Merck's MRL Ventures, Norwest, Novo Holdings, and Platanus.
- RayTx's lead program RTx-015 is being evaluated in the Phase I ENVISION study (NCT06460844) in retinitis pigmentosa; second program RTx-021 is in a Phase I/II study (NCT07439887) for Stargardt disease and IND-enabling work for geographic atrophy.
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Investors
Novo HoldingsJanus Henderson InvestorsInvusFranklin TempletonMarshall WaceDeerfield Management4BIO CapitalNorwest Venture PartnersPlatanusMRL Ventures FundAdage Capital Management
Focus areas
Series BBiotechnologyClinical TrialsHealthtechPharmaceuticals
No open roles on the board yet
We do not have indexed listings for Ray Therapeutics right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts